CN113476505B - Traditional Chinese medicine composition for treating knee joint degenerative disease and application thereof - Google Patents
Traditional Chinese medicine composition for treating knee joint degenerative disease and application thereof Download PDFInfo
- Publication number
- CN113476505B CN113476505B CN202110936016.3A CN202110936016A CN113476505B CN 113476505 B CN113476505 B CN 113476505B CN 202110936016 A CN202110936016 A CN 202110936016A CN 113476505 B CN113476505 B CN 113476505B
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- traditional chinese
- stem
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A41—WEARING APPAREL
- A41D—OUTERWEAR; PROTECTIVE GARMENTS; ACCESSORIES
- A41D13/00—Professional, industrial or sporting protective garments, e.g. surgeons' gowns or garments protecting against blows or punches
- A41D13/05—Professional, industrial or sporting protective garments, e.g. surgeons' gowns or garments protecting against blows or punches protecting only a particular body part
- A41D13/06—Knee or foot
- A41D13/065—Knee protectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/254—Acanthopanax or Eleutherococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/714—Aconitum (monkshood)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/716—Clematis (leather flower)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M35/00—Devices for applying media, e.g. remedies, on the human body
- A61M35/10—Wearable devices, e.g. garments, glasses or masks
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Textile Engineering (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicine composition for treating knee joint degenerative disease and application thereof. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 10-20 parts of radix angelicae pubescentis, 10-20 parts of radix clematidis, 3-9 parts of prepared kusnezoff monkshood root, 25-35 parts of garden balsam stem, 10-20 parts of kadsura pepper stem, 10-20 parts of cassia twig, 10-20 parts of caulis spatholobi, 10-20 parts of cynanchum paniculatum, 10-20 parts of lycopodium clavatum, 5-15 parts of safflower and 10-20 parts of cortex acanthopanacis. The pubescent angelica root, clematis root, paniculate swallowwort root and cassia twig are used as monarch drugs for removing arthralgia by warming and activating, the acanthopanax bark, the prepared kusnezoff monkshood root, the safflower and the suberect spatholobus stem are used as ministerial drugs for dispelling cold and dampness and promoting blood circulation and relieving pain, the common clubmoss herb and the garden balsam stem are used as adjuvant drugs for relaxing muscles and tendons and relieving pain, and the futokadsura stem is used as guide drug for dredging collaterals, and all the drugs supplement each other and have synergistic effect. Animal experiments show that the drug effect for treating knee joint degenerative changes is remarkable, and the knee joint pain degree, the joint movement degree, the swelling degree and the gait of an animal model can be obviously improved.
Description
Technical Field
The invention relates to the field of traditional Chinese medicine compositions, in particular to a traditional Chinese medicine composition for treating knee joint pain caused by knee joint degenerative change and application thereof.
Background
Degenerative knee joint diseases, also known as osteoarthritis, osteoarthropathy, degenerative joint diseases, proliferative arthritis, hypertrophic arthritis, senile arthritis, etc., are the most common chronic and progressive joint diseases. The pathological features of the medicine are degeneration and destruction of articular cartilage, subchondral bone sclerosis, reactive hyperplasia of articular margin and subchondral bone and osteophyte formation. It is clinically manifested as swollen knee joints, pain, difficulty walking, difficulty standing up and squatting. The disease belongs to the category of arthralgia in traditional Chinese medicine, and currently, the old is generally considered to have liver and kidney deficiency and muscles and bones are not nourished; long-term strain, blood stasis and qi stagnation; the three factors of wind-cold-dampness obstructing the meridians and collaterals are the root of the disease. The treatment of degenerative knee joint diseases is mainly conservative treatment. Can be used for comprehensive treatment by oral administration, fumigation and washing, acupuncture, massage, physiotherapy, and exercise therapy.
Patent document CN103536777A, published japanese patent No. 2014.01.29, discloses a traditional Chinese medicine composition for treating knee osteoarthritis, which comprises the following traditional Chinese medicine raw materials in parts by weight: 5-25 parts of clematis root, 5-25 parts of parasitic loranthus, 5-25 parts of lycopodium clavatum, 10-30 parts of suberect spatholobus stem, 5-25 parts of medicinal cyathula root, 10-30 parts of pawpaw, 5-25 parts of rhizoma corydalis, 5-20 parts of divaricate saposhnikovia root, 5-20 parts of incised notopterygium rhizome, 5-20 parts of doubleteeth pubescent angelica root, 5-25 parts of large-leaved gentian, 5-25 parts of largehead atractylodes rhizome, 5-25 parts of poria, 5-20 parts of amur corktree bark, 5-20 parts of swordlike atractylodes rhizome, 5-25 parts of Chinese angelica, 5-15 parts of cassia twig, 5-25 parts of tall gastrodia tuber, 5-25 parts of paniculate swallowwort root, 5-15 parts of pseudo-ginseng and 5-15 parts of liquorice. It is administered by decocting with water. Has the effects of nourishing yin, tonifying kidney, eliminating phlegm, expelling wind, reducing swelling, relieving pain, promoting blood circulation, removing blood stasis and strengthening muscles and bones, and has obvious curative effect on treating knee osteoarthritis.
Patent document CN112274613A, published japanese patent No. 2021.01.29, discloses a traditional Chinese medicine composition for treating knee osteoarthritis, which is composed of the following traditional Chinese medicinal materials in parts by mass: 3-10 parts of cassia twig, 3-10 parts of folium artemisiae argyi, 3-10 parts of garden balsam stem, 3-10 parts of paniculate swallowwort root, 2-6 parts of notopterygium root, 3-10 parts of radix angelicae pubescentis, 2-6 parts of erythrina bark, 2-6 parts of herba siegesbeckiae, 1.5-5 parts of prepared radix aconiti, 2-6 parts of rhizoma sparganii, 2-6 parts of curcuma zedoary, 2-6 parts of sappan wood, 2-10 parts of lycopodium clavatum, 2-6 parts of herba lycopi, 5-10 parts of radix clematidis, 1-5 parts of asarum, 4-10 parts of rhizoma curcumae longae and 1-5 parts of prepared radix aconiti agrestis. The application method comprises grinding the above materials into powder, and decocting to obtain decoction for fumigation. Can be used for treating knee osteoarthritis, and relieving pain and edema.
However, the development of a specific Chinese medicinal composition with low drug effect is still necessary. At present, no traditional Chinese medicine composition which has an obvious curative effect on knee joint degenerative disease and has few medicinal ingredients is available.
Disclosure of Invention
The invention aims to provide a traditional Chinese medicine composition for treating knee joint degenerative disease aiming at the defects in the prior art.
Another object of the present invention is to provide the use of the said Chinese medicinal composition.
Still another object of the present invention is to provide a knee pad pack for treating degenerative knee joint diseases.
In order to solve the first technical problem, the invention adopts the technical scheme that:
a traditional Chinese medicine composition for treating knee joint degenerative disease is prepared from the following raw material medicines in parts by weight: 10-20 parts of radix angelicae pubescentis, 10-20 parts of radix clematidis, 3-9 parts of prepared kusnezoff monkshood root, 25-35 parts of garden balsam stem, 10-20 parts of kadsura pepper stem, 10-20 parts of cassia twig, 10-20 parts of caulis spatholobi, 10-20 parts of cynanchum paniculatum, 10-20 parts of lycopodium clavatum, 5-15 parts of safflower and 10-20 parts of cortex acanthopanacis.
As a preferred example of the invention, the traditional Chinese medicine composition is prepared from the following raw medicines in parts by weight: 12-18 parts of radix angelicae pubescentis, 12-18 parts of radix clematidis, 5-7 parts of prepared radix aconiti agrestis, 28-32 parts of garden balsam stem, 12-18 parts of kadsura pepper stem, 12-18 parts of cassia twig, 12-18 parts of caulis spatholobi, 12-18 parts of cynanchum paniculatum, 12-18 parts of lycopodium clavatum, 8-12 parts of safflower carthamus and 12-18 parts of cortex acanthopanacis.
More preferably, the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 15 parts of radix angelicae pubescentis, 15 parts of radix clematidis, 6 parts of prepared kusnezoff monkshood root, 30 parts of garden balsam stem, 15 parts of kadsura pepper stem, 15 parts of cassia twig, 15 parts of caulis spatholobi, 15 parts of cynanchum paniculatum, 15 parts of lycopodium clavatum, 10 parts of safflower and 15 parts of cortex acanthopanacis.
As another preferable example of the invention, the dosage form of the traditional Chinese medicine composition is an external dosage form.
More preferably, the external preparation is powder, lotion, patch, ointment, gel, paste, film coating agent, cataplasm or aerosol for external use.
In order to solve the second technical problem, the invention adopts the technical scheme that:
the application of the traditional Chinese medicine composition in preparing a medicine for treating knee joint degenerative disease through external application.
As a preferred embodiment of the invention, the treatment of the knee joint degenerative disease refers to improvement of knee joint pain, limited movement, swelling or gait caused by the knee joint degenerative disease.
In order to solve the third technical problem, the invention adopts the technical scheme that:
a knee pad bag for treating knee joint degenerative disease contains the Chinese medicinal composition.
The invention has the advantages that:
1. the traditional Chinese medicine composition is prepared from radix angelicae pubescentis, radix clematidis, paniculate swallowwort root and cassia twig which are mild medicines for removing arthralgia, wherein the radix angelicae pubescentis mainly enters kidney meridian, and has good descending property, particularly waist, knee, leg and foot pain and arthralgia which belong to cold-dampness in lower part; the paniculate swallowwort root and the clematis root can expel wind-damp, dredge collaterals and relieve pain; the cassia twig, pungent, sweet and warm in nature, has the effects of warming and dredging yang qi of the human body, combines the four medicines, can not only eliminate pathogenic wind, cold and dampness of lower limbs to treat the root, but also warm and dredge channels and collaterals to relieve pain and eliminate symptoms; cortex acanthopanacis, radix aconiti kusnezoffii preparata, safflower carthamus and caulis spatholobi are used as assistant drugs for strengthening the functions of dispelling cold and dampness, promoting blood circulation and relieving pain, lycopodium clavatum and speranskia herb are used as assistant drugs for relaxing muscles and tendons and relieving pain, and caulis piperis futokadsurae is used for dredging collaterals. Animal experiments show that the drug effect for treating knee joint degenerative changes is remarkable, and the knee joint pain degree, the joint movement degree, the swelling degree and the gait of an animal model can be obviously improved.
2. The traditional Chinese medicine composition has fewer medicinal ingredients, is more convenient to prepare, and reduces the cost.
3. The traditional Chinese medicine composition is administrated in an external mode, and does not have a liver first-pass effect, so that the bioavailability of the medicine is improved, and the hepatotoxicity is reduced.
Detailed Description
The following provides a detailed description of specific embodiments of the present invention.
EXAMPLE 1 preparation of powder for external use of the Chinese medicinal composition of the present invention
Weighing the following raw material medicines in parts by weight: 15 parts of radix angelicae pubescentis, 15 parts of radix clematidis, 6 parts of prepared kusnezoff monkshood root, 30 parts of garden balsam stem, 15 parts of kadsura pepper stem, 15 parts of cassia twig, 15 parts of caulis spatholobi, 15 parts of cynanchum paniculatum, 15 parts of lycopodium clavatum, 10 parts of safflower and 15 parts of cortex acanthopanacis, and the components are crushed and mixed uniformly to obtain the external powder.
EXAMPLE 2 preparation of powder for external use of the Chinese medicinal composition of the present invention
Weighing the following raw material medicines in parts by weight: 20 parts of radix angelicae pubescentis, 10 parts of radix clematidis, 9 parts of prepared kusnezoff monkshood root, 25 parts of garden balsam stem, 20 parts of kadsura pepper stem, 10 parts of cassia twig, 20 parts of caulis spatholobi, 10 parts of cynanchum paniculatum, 20 parts of lycopodium clavatum, 5 parts of safflower and 20 parts of cortex acanthopanacis, and the components are crushed and mixed uniformly to obtain the external powder.
EXAMPLE 3 preparation of powder for external use of the Chinese medicinal composition of the present invention (III)
Weighing the following raw material medicines in parts by weight: 20 parts of radix angelicae pubescentis, 20 parts of radix clematidis, 9 parts of prepared kusnezoff monkshood root, 25 parts of garden balsam stem, 10 parts of kadsura pepper stem, 10 parts of cassia twig, 20 parts of caulis spatholobi, 20 parts of cynanchum paniculatum, 20 parts of lycopodium clavatum, 5 parts of safflower and 10 parts of cortex acanthopanacis, and the components are crushed and mixed uniformly to obtain the external powder.
Example 4 preparation of powder for external use of the Chinese medicinal composition of the present Invention (IV)
Weighing the following raw material medicines in parts by weight: 20 parts of radix angelicae pubescentis, 20 parts of radix clematidis, 9 parts of prepared kusnezoff monkshood root, 25 parts of garden balsam stem, 10 parts of kadsura pepper stem, 10 parts of cassia twig, 10 parts of caulis spatholobi, 20 parts of cynanchum paniculatum, 10 parts of lycopodium clavatum, 15 parts of safflower and 10 parts of cortex acanthopanacis, and the components are crushed and mixed uniformly to obtain the external powder.
EXAMPLE 5 preparation of powder for external use of the Chinese medicinal composition of the present invention (V)
Weighing the following raw material medicines in parts by weight: 10 parts of radix angelicae pubescentis, 20 parts of radix clematidis, 3 parts of prepared kusnezoff monkshood root, 35 parts of garden balsam stem, 10 parts of kadsura pepper stem, 20 parts of cassia twig, 10 parts of caulis spatholobi, 20 parts of cynanchum paniculatum, 10 parts of lycopodium clavatum, 15 parts of safflower and 10 parts of cortex acanthopanacis, and the components are crushed and mixed uniformly to obtain the external powder.
EXAMPLE 6 preparation of powder for external use of the Chinese medicinal composition of the present invention (VI)
Weighing the following raw material medicines in parts by weight: 18 parts of radix angelicae pubescentis, 12 parts of radix clematidis, 7 parts of prepared kusnezoff monkshood root, 28 parts of garden balsam stem, 18 parts of kadsura pepper stem, 12 parts of cassia twig, 18 parts of caulis spatholobi, 12 parts of cynanchum paniculatum, 18 parts of lycopodium clavatum, 8 parts of safflower and 18 parts of cortex acanthopanacis, and the components are crushed and mixed uniformly to obtain the external powder.
EXAMPLE 7 preparation of powder for external use of the Chinese medicinal composition of the present invention (VII)
Weighing the following raw material medicines in parts by weight: 12 parts of radix angelicae pubescentis, 12 parts of radix clematidis, 5 parts of prepared kusnezoff monkshood root, 28 parts of garden balsam stem, 18 parts of kadsura pepper stem, 18 parts of cassia twig, 18 parts of caulis spatholobi, 18 parts of cynanchum paniculatum, 12 parts of lycopodium clavatum, 8 parts of safflower and 12 parts of cortex acanthopanacis, and the components are crushed and mixed uniformly to obtain the external powder.
EXAMPLE 8 preparation of powder for external use of the Chinese medicinal composition of the present invention (VIII)
Weighing the following raw material medicines in parts by weight: 12 parts of radix angelicae pubescentis, 18 parts of radix clematidis, 5 parts of prepared kusnezoff monkshood root, 32 parts of garden balsam stem, 12 parts of kadsura pepper stem, 18 parts of cassia twig, 12 parts of caulis spatholobi, 18 parts of cynanchum paniculatum, 12 parts of lycopodium clavatum, 12 parts of safflower and 12 parts of cortex acanthopanacis, and the components are crushed and mixed uniformly to obtain the external powder.
Example 9 preparation of powder for external use of the Chinese medicinal composition of the present invention (nine)
Weighing the following raw material medicines in parts by weight: 18 parts of radix angelicae pubescentis, 18 parts of radix clematidis, 7 parts of prepared radix aconiti agrestis, 28 parts of garden balsam stem, 12 parts of kadsura pepper stem, 12 parts of cassia twig, 18 parts of caulis spatholobi, 12 parts of cynanchum paniculatum, 18 parts of lycopodium clavatum, 8 parts of safflower and 12 parts of cortex acanthopanacis, and the components are crushed and mixed uniformly to obtain the external powder.
Example 10 preparation of powder for external use of the Chinese medicinal composition of the present invention (ten)
Weighing the following raw material medicines in parts by weight: 12 parts of radix angelicae pubescentis, 18 parts of radix clematidis, 5 parts of prepared kusnezoff monkshood root, 32 parts of garden balsam stem, 12 parts of kadsura pepper stem, 18 parts of cassia twig, 10 parts of caulis spatholobi, 20 parts of cynanchum paniculatum, 10 parts of lycopodium clavatum, 15 parts of safflower and 10 parts of cortex acanthopanacis, and the components are crushed and mixed uniformly to obtain the external powder.
EXAMPLE 11 preparation of Patches of the Chinese medicinal composition of the present invention
(1) Taking the traditional Chinese medicine composition in any one of embodiments 1-10, adding 8-10 times of water, decocting for 2 times, each time for 1.5 hours, filtering while hot, and combining liquid medicines decocted twice for later use;
(2) vacuum concentrating the above medicinal liquid under reduced pressure, removing water solution, and vacuum drying the obtained extract;
(3) weighing 2g of the extract powder, adding 2-6ml of medicinal glycerol, blending into paste, adding 0.3-2 g of borneol, uniformly mixing, uniformly spreading on a square medical adhesive plaster with a fixed size, and reserving a certain size at the periphery for fixing the adhesive plaster.
EXAMPLE 12 preparation of lotion of the Chinese medicinal composition of the present invention
Taking the traditional Chinese medicine composition described in any one of embodiments 1-10, adding 8-10 times of water, decocting for 2 times, each time for 1.5 hours, filtering while hot, and combining the liquid medicines decocted twice to obtain the traditional Chinese medicine composition.
EXAMPLE 13 preparation of the ointment of the Chinese medicinal composition of the present invention
(1) Taking the traditional Chinese medicine composition in any one of embodiments 1-10, adding 8-10 times of water, decocting for 2 times, each time for 1.5 hours, filtering while hot, and combining liquid medicines decocted twice for later use;
(2) vacuum concentrating the above medicinal liquid under reduced pressure to obtain concentrated solution, adding Cera flava and yellow Vaseline, decocting with slow fire, stirring, and cooling to obtain paste.
EXAMPLE 14 preparation of gel of the Chinese medicinal composition of the present invention
(1) Taking the traditional Chinese medicine composition in any one of embodiments 1-10, adding 8-10 times of water, decocting for 2 times, 1.5 hours each time, filtering while hot, and combining liquid medicines decocted for standby;
(2) vacuum concentrating the above medicinal liquid to obtain concentrated solution; adding carbomer into glycerol, grinding to moisten, adding small amount of distilled water, grinding, transferring into a measuring cup, dissolving triethanolamine, ethylparaben and distilled water in appropriate amount, stirring to obtain gel, adding appropriate amount of distilled water, and stirring; adding the above concentrated solution, and grinding.
EXAMPLE 15 preparation of the Chinese medicinal composition cataplasm of the present invention
(1) Taking the traditional Chinese medicine composition in any one of embodiments 1-10, adding 8-10 times of water, decocting for 2 times, 1.5 hours each time, filtering while hot, and combining liquid medicines decocted for standby;
(2) vacuum concentrating the above medicinal liquid under reduced pressure to obtain concentrated solution, adding conventional cataplasma matrix such as sorbitol and glycerol, stirring, coating on support layer, and adding protective layer.
EXAMPLE 16 preparation of a Knee pack of the Chinese medicinal composition of the present invention
An appropriate amount of the Chinese medicinal composition of any one of embodiments 1-10 is sewn into a cloth bag which can be fixed around the knee.
Example 17 animal experiment of the Chinese medicinal composition of the present invention for treating degenerative knee joint diseases
1 materials and methods
1.1 Experimental materials
1.1.1 Experimental animals
50 healthy Japanese male big-ear white rabbits (6 months old) with a body weight of 2.0-2.5kg were purchased from Duoduoshu laboratory animals Co., Ltd. One week of adaptive feeding before the experiment.
1.1.2 therapeutic Agents
The knee pad bag made of the traditional Chinese medicine composition comprises the following components: the traditional Chinese medicine composition powder is prepared according to the proportion of the embodiment 1, and then the powder is filled into a self-made knee pad bag. The knee pad bag is made of cotton cloth, the front side of the knee pad bag is a square medicated bag with one side being 4cm long, and two elastic laces are respectively sewn on two sides of the medicated bag and used for wrapping and fixing the knees of animals.
The knee pad bag prepared by the contrast traditional Chinese medicine composition comprises the following components: as above, the composition of the raw materials of the Chinese medicinal composition is different, and specifically comprises: 15 parts of radix angelicae pubescentis, 15 parts of radix clematidis, 6 parts of prepared kusnezoff monkshood root, 30 parts of garden balsam stem, 15 parts of kadsura pepper stem, 15 parts of cassia twig, 15 parts of caulis spatholobi, 15 parts of cynanchum paniculatum, 15 parts of lycopodium clavatum, 10 parts of ligusticum wallichii and 15 parts of loranthus parasiticus.
Sodium hyaluronate: purchased from Shanghai Jingfeng pharmaceuticals, Inc., and assigned the national drug Standard H20000159.
1.1.3 Primary reagents
Chloral hydrate, various concentrations of ethanol, xylene, paraffin, distilled water, hematoxylin dye, eosin dye, TNF-alpha radioimmunoassay kit and MMP-3 radioimmunoassay kit (Beijing Ke Meidong Yao Biotech Co., Ltd.).
1.1.4 Main laboratory Instrument
Centrifuge, electronic balance, cryorefrigerator, Leica paraffin embedding machine, Leica paraffin slicer, Olympus microscope.
1.2 Experimental methods
1.2.1 Molding
And (4) molding by adopting a left hind limb straightening position fixing method. Animals are fasted for 16 hours before molding, and 30mg/kg of 3% sodium pentobarbital solution is injected into ear margin vein. After anesthesia, the shaver unhairing of the left hind limb of the rabbit is carried out from the hip joint to the toe, the knee joint is stretched to 150-. Immersing the plaster bandage in hot water of 80 ℃, softening, winding the left hind limb of the rabbit from the groin to the toes, exposing the toes to observe the blood supply condition, finally fixing by the bandage, and winding gauze to prevent biting. The braking condition and the toe blood flow condition are observed twice a day during the molding period, and the restraint is released after 6 weeks.
1.2.2 grouping and treatment
Purchased japanese male big-ear white rabbits were randomly divided into normal and construction groups. After the molding of the molding set is successful, the molding set is randomly divided into a model set, a knee pad treatment set of the invention, a control knee pad treatment set and a sodium hyaluronate treatment set, and each set comprises 10 patients. The knee pad bag treatment group and the comparison knee pad bag treatment group are fixed on the knee joints of rabbits by using corresponding knee pad bags, and the medicine bags are positioned right in front of the knee joints and are used for 12 hours every day. The sodium hyaluronate treatment group is given sodium hyaluronate articular injection once a week, 0.3ml each time. The normal and model groups used cotton-filled knee wraps to simulate treatment. Treatment was continued for 4 weeks.
1.2.3 Observation index
1.2.3.1 Lequesne MG score evaluation
The knee joint and ethological change conditions of the rabbits in each group are evaluated according to a Lequesne MG scale modified before treatment, namely after the molding is finished and after the treatment. Scoring and recording the total score by the same blinded non-experimenter, and the scoring standard is shown in table 1.
TABLE 1 Lequesne MG Scale
1.2.3.2 Observation of HE staining of cartilage in Knee Joint
After treatment, all rabbits are killed by an air embolism method, about 50mg cartilage specimens of the median cartilage of the knee joint surface are cut by using an ophthalmic scissors and a sharp blade, the cartilage specimens are cleaned by 0.9% of physiological saline, and then the cartilage specimens are directly placed in neutral formaldehyde with the volume fraction of 4% for fixing for 72 hours, dehydrated, embedded in paraffin, sliced and subjected to HE staining to observe the pathological morphology of the knee joint cartilage.
1.2.3.3 determination of TNF-alpha and MMP-3 content in cartilage tissue
Cutting about 50mg cartilage specimen of the median cartilage of knee articular surface with ophthalmic scissors and sharp blade, cleaning with 0.9% physiological saline, cutting, adding 0.9% physiological saline, homogenizing, freezing and centrifuging homogenate, collecting supernatant, and detecting the contents of TNF-alpha and MMP-3 in cartilage tissue according to the kit instructions
1.2.3.4 statistical methods
The data were processed using software SPSS23.0 and the measurements were expressed as means ± standard deviation. Data were analyzed using one-way ANOVA, and pairwise differences between groups were examined using LSD, with P <0.05 being statistically significant.
3 results of the experiment
3.1 groups Lequesne MG scores
The model group and the treatment groups all have reduced scores of local pain stimulation response, gait, range of joint motion and joint swelling degree of rabbits before and after treatment (tables 2-5). The Lequesne MG score of each group before treatment was significantly higher than that of the normal group (P <0.05), indicating that the modeling was successful and significant OA characteristics appeared in the knee joints and the behaviours of the rabbits. The Lequesne MG score observed after treatment was significantly reduced for each group compared to the Lequesne MG score observed before treatment (P <0.05), but the Lequesne MG score for each treatment group was significantly less than that of the model group (P <0.05), with the lowest Lequesne MG score for the rabbits of the knee wrap treatment group of the present invention, indicating the most significant improvement in the OA model knee joint (table 6).
TABLE 2 local pain stimulus response scores before and after treatment for each group
TABLE 3 gait scores before and after treatment for each group
TABLE 4 Joint Range of motion scores before and after treatment for each group
TABLE 5 Joint swelling degree score before and after treatment for each group
TABLE 6 comparison of Lequesne MG scores before and after treatment for each group
P <0.05 compared to normal group before treatment; compared with the group before treatment, # P < 0.05; compared to the model group post-treatment, Δ P < 0.05.
3.2 Rabbit Knee cartilage HE staining in groups
HE staining observation is carried out on knee joint cartilage of each group of rabbits, and the knee joint cartilage cells of the normal group of rabbits are uniform in distribution, fusiform in shape and normal in arrangement. The cartilage cells of the knee joint of the model group rabbits are not uniformly distributed, a large number of cell clusters are gathered, the arrangement is disordered, and the rabbit has obvious inflammatory infiltration. The cartilage cells of each treatment group are distributed more uniformly, the aggregation of cell clusters is less, the arrangement is more regular, and inflammatory cells are obviously less than those of the model group.
3.3 TNF-alpha and MMP-3 content in cartilage of knee joint of various groups of rabbits
Compared with the normal group, the contents of TNF-alpha and MMP-3 in the knee joint cartilage of the model group of rabbits are obviously increased (P is less than 0.05), which indicates that inflammation occurs and the protein for promoting the cartilage matrix destruction is increased. Compared with the model group, the contents of TNF-alpha and MMP-3 in the knee joint cartilage of the rabbits in each treatment group are remarkably reduced (P is less than 0.05), wherein the contents of TNF-alpha and MMP-3 in the knee joint cartilage of the rabbits in the treatment group with the knee pad of the invention are the lowest, which shows that the knee pad of the invention can remarkably reduce the inflammation of the bone joint cartilage caused by OA and reduce the expression of MMP-3 causing the degenerative change of the cartilage (Table 7).
TABLE 7 comparison of TNF-alpha and MMP-3 content in cartilage of knee joint of rabbits of each group
P <0.05 compared to normal group; compared to the model group, # P < 0.05.
The above description is only a preferred embodiment of the present invention, and it should be noted that, for a person skilled in the art, several modifications and additions can be made without departing from the method of the present invention, and these modifications and additions should also be considered as the protection scope of the present invention.
Claims (8)
1. The traditional Chinese medicine composition for treating knee joint degenerative disease is characterized by being prepared from the following raw material medicines in parts by weight: 10-20 parts of radix angelicae pubescentis, 10-20 parts of radix clematidis, 3-9 parts of prepared radix aconiti agrestis, 25-35 parts of garden balsam stem, 10-20 parts of kadsura pepper stem, 10-20 parts of cassia twig, 10-20 parts of caulis spatholobi, 10-20 parts of paniculate swallowwort root, 10-20 parts of lycopodium clavatum, 5-15 parts of safflower and 10-20 parts of cortex acanthopanacis.
2. The traditional Chinese medicine composition according to claim 1, which is prepared from the following raw material medicines in parts by weight: 12-18 parts of radix angelicae pubescentis, 12-18 parts of radix clematidis, 5-7 parts of prepared kusnezoff monkshood root, 28-32 parts of garden balsam stem, 12-18 parts of kadsura pepper stem, 12-18 parts of cassia twig, 12-18 parts of suberect spatholobus stem, 12-18 parts of paniculate swallowwort root, 12-18 parts of lycopodium clavatum, 8-12 parts of safflower and 12-18 parts of cortex acanthopanacis.
3. The traditional Chinese medicine composition according to claim 2, which is prepared from the following raw materials in parts by weight: 15 parts of radix angelicae pubescentis, 15 parts of radix clematidis, 6 parts of prepared kusnezoff monkshood root, 30 parts of garden balsam stem, 15 parts of kadsura pepper stem, 15 parts of cassia twig, 15 parts of caulis spatholobi, 15 parts of cynanchum paniculatum, 15 parts of lycopodium clavatum, 10 parts of safflower and 15 parts of cortex acanthopanacis.
4. The traditional Chinese medicine composition of claim 1, wherein the dosage form of the traditional Chinese medicine composition is an external dosage form.
5. The composition of claim 4, wherein the topical formulation is a topical powder, lotion, patch, ointment, gel, paste, film, cataplasm or topical aerosol.
6. The use of the Chinese medicinal composition of any one of claims 1-5 in the preparation of a medicament for the topical treatment of degenerative changes in the knee joint.
7. The use of claim 6, wherein treating knee degeneration is ameliorating knee pain, limited mobility, swelling, or gait due to knee degeneration.
8. A knee pad pack for treating degenerative changes of the knee joint, which contains the Chinese medicinal composition as claimed in any one of claims 1 to 5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110936016.3A CN113476505B (en) | 2021-08-16 | 2021-08-16 | Traditional Chinese medicine composition for treating knee joint degenerative disease and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110936016.3A CN113476505B (en) | 2021-08-16 | 2021-08-16 | Traditional Chinese medicine composition for treating knee joint degenerative disease and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113476505A CN113476505A (en) | 2021-10-08 |
| CN113476505B true CN113476505B (en) | 2022-07-05 |
Family
ID=77945350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110936016.3A Active CN113476505B (en) | 2021-08-16 | 2021-08-16 | Traditional Chinese medicine composition for treating knee joint degenerative disease and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113476505B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113975365A (en) * | 2021-12-07 | 2022-01-28 | 上海市普陀区人民医院(上海纺织第一医院) | Traditional Chinese medicine composition for treating arthritis and application thereof |
-
2021
- 2021-08-16 CN CN202110936016.3A patent/CN113476505B/en active Active
Non-Patent Citations (1)
| Title |
|---|
| 中西医结合治疗膝关节骨性关节炎临床观察;潘刘英;《中华中医药学刊》;20130331;第31卷(第3期);682-684 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113476505A (en) | 2021-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104208580A (en) | Traditional Chinese medicine composition for treating rheumatoid bone pain and preparation method thereof | |
| CN105998211B (en) | It is a kind of can improve microcirculation, promoting menstruation relax network, activating microcirculation and removing stasis medicinal, treat rheumatism bone disease external drug preparation method | |
| CN113476505B (en) | Traditional Chinese medicine composition for treating knee joint degenerative disease and application thereof | |
| CN103263659A (en) | Traditional Chinese medicine composition for treating rheumatism bone diseases | |
| US20160015767A1 (en) | External-use traditional chinese medicine for ichthyosis and xerodermia, and preparation method thereof | |
| CN110638987A (en) | Moxibustion medicinal moxibustion stick for dispelling cold and eliminating dampness and preparation method thereof | |
| CN109432269A (en) | A kind of Chinese medicine composition and preparation method, purposes | |
| CN113768975A (en) | Traditional Chinese medicine composition for treating arthralgia, traditional Chinese medicine patch, and preparation method and use method thereof | |
| CN106822377B (en) | Compound osteitis cataplasm patch and preparation method thereof | |
| CN101244241A (en) | Cunt shrinking and maintaining agent for gynaecologic treatment | |
| CN104800720A (en) | Medicine for improving sexual desire of breeding bull and increasing yield of semen and preparation method of medicine | |
| CN107007714A (en) | It is a kind of that there is the exterior-applied medical wine for promoting poroma nucleus formation | |
| CN103690583A (en) | Medicinal liquor, and preparation method and application thereof | |
| CN111358915A (en) | Traditional Chinese medicine for treating congenital muscular torticollis and preparation method thereof | |
| CN102512560A (en) | Traditional Chinese medicinal composition for treating arthromyodynia | |
| CN107998235B (en) | Compound Zhuang medicine for treating ankle sprain and preparation method thereof | |
| CN112656924A (en) | A Chinese medicinal composition with antiinflammatory, analgesic, and antibacterial effects, and its preparation method | |
| CN111991527A (en) | Foot medicated bath formula and preparation process thereof | |
| CN105079206A (en) | Pain relieving traditional Chinese medicine composition and preparation method thereof | |
| CN110559417A (en) | gout-relieving moxibustion stick and preparation method thereof | |
| CN106109802B (en) | Traditional Chinese medicine composition for treating primary dysmenorrhea and preparation method and application thereof | |
| CN104042944A (en) | Medicinal preparation used for treating chloasma | |
| CN115006462B (en) | Traditional Chinese medicine composition for treating arthritis and lozenge thereof | |
| CN103301373A (en) | Pharmaceutical composition for treating postpartum perineal mucosal lesions | |
| CN112755134B (en) | Plaster for treating hyperosteogeny and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |